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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYFibrodysplasia ossificans progressiva (FOP) is a rare disease characterized by progressive ossification of soft tissues, for which there is
no effective treatment. Mutations in the bone morphogenetic protein (BMP) type I receptor activin receptor-like kinase 2 (ACVR1/
ALK2) are the main cause of FOP. We generated human induced pluripotent stem cells (hiPSCs) from FOP patients with the ALK2
R206Hmutation. The mutant ALK2 gene changed differentiation efficiencies of hiPSCs into FOP bone-forming progenitors: endothelial
cells (ECs) and pericytes. ECs from FOP hiPSCs showed reduced expression of vascular endothelial growth factor receptor 2 and could
transform into mesenchymal cells through endothelial-mesenchymal transition. Increasedmineralization of pericytes from FOP hiPSCs
could be partly inhibited by the ALK2 kinase inhibitor LDN-212854. Thus, differentiated FOP hiPSCs recapitulate some aspects of the
disease phenotype in vitro, and they could be instrumental in further elucidating underlying mechanisms of FOP and development
of therapeutic drug candidates.INTRODUCTION
Fibrodysplasia ossificans progressiva (FOP) is an autosomal
dominant genetic disorder in which acute inflammation
may trigger the formation of a second skeleton of hetero-
topic bone. Classic FOP is caused by gain-of-functionmuta-
tion (617G > A; R206H) in the activin receptor-like kinase
2 (ACVR1/ALK2) gene, encoding the bone morphogenetic
protein (BMP) type I receptor (Shore et al., 2006). Enhanced
BMP signaling in patients with the ALK2 R206H mutation
has been attributed to loss of inhibitory activity of
the ALK2-interacting protein FK506-binding protein-12
(FKBP12) (Chaikuad et al., 2012; van Dinther et al.,
2010). Previous publications indicated that Tie2+ endothe-
lial cells (ECs) andmesenchymal cells (MCs) contributed as
progenitor cells to the episodic heterotopic ossification
(HO) in FOP (Medici et al., 2010; Wosczyna et al., 2012).
Other cells like circulating osteogenic precursors, skeletal
myoblasts, and vascular smooth muscle cells also were
found in FOP lesions andmay contribute toHO in FOP (He-
gyi et al., 2003; Lounev et al., 2009; Suda et al., 2009).
Despite recent advances in understanding of the disease
(Hatsell et al., 2015), to date there is no cure or even treat-
ment for HO in FOP. A comprehensive understanding of
the molecular mechanisms underlying abnormal behavior
of bone-forming progenitor cells in FOP could be one
approach toward effective treatment for HO in FOP, andStem Cellto other more prevalent situations with HO that, for
example,may occur after traumatic accidents or deep tissue
burns. The traditional way of obtaining human biopsy tis-
sues from FOP patients is limited as physical and surgical
injury can induce HO. New protocols to produce well-char-
acterized FOP bone-forming progenitor cells for research
and therapeutic drug screening are needed. The ability to
generate human induced pluripotent stem cells (hiPSCs)
(Takahashi et al., 2007) from adult tissues provides new op-
portunities for research on FOP. If derived from patients
with genetic disease, hiPSCs allow production of large
numbers of diseased target cells for basic research and
drug development since they are immortal and pluripotent
(Sterneckert et al., 2014).
In this study, we generated FOP hiPSCs from kidney cells
isolated from urine by episomal vectors. The expression of
pluripotent markers and ability to form derivatives of the
three germ layers were comparable in FOP and control
hiPSCs. However, the mutation in ALK2 reduced the effi-
ciency of differentiation of hiPSCs into ECs and affected
the phenotypes of ECs and pericytes. The hiPSC-derived
ECs (hiPSC-ECs) from FOP patients exhibited reduced
expression of vascular endothelial growth factor receptor 2
(VEGFR2) and could be transformed into MCs through
endothelial-mesenchymal transition (EndMT). The hiPSC-
derived pericytes (hiPSC-pericytes) from the FOP group
showed increased ability to mineralize compared with theReports j Vol. 5 j 963–970 j December 8, 2015 j ª2015 The Authors 963
control. Our experiments demonstrated that disease-rele-
vant cells differentiated from FOP hiPSCs possessed pheno-
types reminiscent of the FOP disease.RESULTS
Generation of FOP hiPSCs from Urine Cells
We used a rapid and non-invasive procedure to isolate kid-
ney cells in urine from FOP patients (Xue et al., 2013). The
cells were isolated from 50–100 ml middle stream of the
micturition from two male FOP patients (Dutch and Chi-
nese, F2 and F3) diagnosed with the classic R206H muta-
tion and two healthy male donors (Dutch and Chinese,
C2 and C3) (Figure S1B).
A schematic representation of hiPSC generation is shown
in Figure S1A. In summary, cultured cells from urine were
electroporated with episomal vectors containing OCT4,
SOX2,KLF4, and thepCEP4-miR-302-367cluster (containing
miR-302b, c, a,d, andmiR-367) (Xue et al., 2013). Transfected
urine cells were maintained in serum-free mTesR1 medium
supplemented with a cocktail of small molecule inhibitors
to promote reprogramming: CHIR99021, PD0325901,
A83-01, and thiazovivin (Wang et al., 2013). Small colonies
of cells appeared thatprogressively adoptedahumanembry-
onic stemcell (hESC)-likemorphology. SelectedhiPSCswere
picked manually and expanded at day 20; hiPSCs main-
tained their hESC-like morphology with prominent nuclei
and little cytoplasm and stained positive for alkaline phos-
phatase (ALP) (Figure S1B).
The hiPSCs from one healthy donor (C3) and from two
FOP patients (F2 and F3) were characterized; the other con-
trol hiPSC line (UE017C1) was obtained from the Guangz-
hou StemCell Bank produced by the samemethod andwas
characterized previously (Xue et al., 2013). The presence of
classical mutation in the ALK2 gene was confirmed in FOP
hiPSCs (Figure S1C). FOP and control hiPSC karyotypes
were checked before passage 10 and thesewere normal (Fig-
ure S1D). The loss of exogenous reprogramming factors
and episomal backbones was demonstrated by genomic
PCR that specifically amplifies exogenous factors (Fig-
ure S1E). The quantitative real-time PCR analysis revealed
that, compared to urine cells, FOP hiPSCs had upregulated
expression of endogenous hESC transcriptional genes
(endogenous OCT4, endogenous SOX2, NANOG, and
REX1), and they had expression levels comparable with
established H1 hESCs (Figure S1F). Immunofluorescence
microscopy showed expression of pluripotency-associated
antigens OCT4, SSEA-4, TRA-1-60, and TRA-1-81 (Fig-
ure S1G). In addition, hiPSCs formed teratomas in mice
in vivo, confirming the pluripotency of FOP iPSCs (Fig-
ure S1H). Therefore, hiPSCs from FOP patients corre-
sponded phenotypically and functionally to hESCs.964 Stem Cell Reports j Vol. 5 j 963–970 j December 8, 2015 j ª2015 The AImpaired EC Differentiation of FOP hiPSCs
A slight elevation of pSMAD1/5 signaling in FOP hiPSCs
compared to control hiPSCs was observed when these cells
were cultured for 24 hr inmediumwith low serum concen-
trations, but not in the undifferentiated FOP iPSCs (Figures
1A and S1I). We differentiated hiPSCs into ECs and peri-
cytes to examine how minor changes in ALK2 R206H/
SMAD signaling influenced the fate of two possible progen-
itor cells of FOP, i.e., ECs and pericytes. On days 10–12
of differentiation, flow cytometry (fluorescence-activated
cell sorting [FACS]) analysis showed that two cell popula-
tions formed as follows: CD31+ ECs and platelet-derived
growth factor receptor (PDGFR) b+ pericytes (Figure 1B).
The generation of CD31+/VE-cadherin+ cells was signifi-
cantly impaired in FOP hiPSCs compared with controls,
while general mesoderm induction was slightly enhanced
in FOP hiPSCs (Figures 1B and 1C).
To verify the FACS data, we examined the expression of
early mesoderm and EC-specific genes (Figure 1D). Differ-
entiation resulted in efficient downregulation of pluripo-
tent markers (OCT4 and NANOG) in the control and
FOP hiPSCs. Primitive streak/mesoderm lineage markers
(T and PDGFRa) were upregulated in FOP hiPSCs on day
4 of differentiation, which may due to the positive effect
of the BMP-signaling pathway on mesoderm formation.
The induction of the early endothelial transcription factor
(ETV2) on day 4 was similar between the two groups. How-
ever, consistent with the FACS data, we observed that endo-
thelial-specific genes (CD31 and CD105) were downregu-
lated in FOP hiPSCs on day 7 of differentiation. Early
pericyte markers PDGFRb and NG2 proteoglycan were ex-
pressed more abundantly in differentiating FOP hiPSCs.
Overall, we observed that the EC differentiation efficiency
was impaired while general mesoderm differentiation was
enhanced in FOP hiPSCs; this difference may due to the
elevated level of ALK2 R206H/SMAD signaling in FOP
compared to control hiPSCs.
Characterization of FOP hiPSC-ECs
Differentiated cell populations were divided into CD31+
ECs and CD31 cells by CD31 antibody-coupled magnetic
bead sorting (Figure 2A). The expression levels of BMP
type I receptors ALK1 and ALK2 were not different in
control versus FOP CD31+ cells (Figure S2A). Sorted FOP
hiPSC-ECs were more sensitive to low concentrations of
BMP6 (5 ng/ml) and the activated BMP signaling could
be inhibited by BMP type I receptor kinase inhibitor
LDN-193189 (Yu et al., 2008; Figure 2B). FOP hiPSC-ECs ex-
hibited poor viability and increased expression of senes-
cence-associated b-galactosidase expression compared to
controls (Figures S2B and S2C). As the VEGF-signaling
pathway is known to regulate survival and proliferation
of ECs through VEGFR2 (Kelly and Hirschi, 2009), weuthors
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Figure 1. Differentiation of FOP hiPSCs
into ECs and Pericytes
(A) Total SMAD1/5 and phospho-SMAD1/5
(pSMAD1/5) level in control hiPSCs (C3-3
and UE017C1) and FOP hiPSCs (F2-6 and
F3-8). Note that the antibodies used here
also may recognize SMAD8 and pSMAD8
bands.
(B) FACS analysis of EC marker (CD31) or
pericyte marker (PDGFRb) expression at
differentiation days 10–12 is shown.
(C) Quantification of the FACS analysis data
for relative percentage of CD31 and VE-cad-
herin double-positive ECs and PDGFRb-pos-
itive pericytes. All values were adjusted
to the control colony C3-3, which is defined
as 1.
(D) Relative gene expression at different
time points during the differentiation.
ACTIN was used to normalize gene ex-
pression.
Data are presented as mean and SD from
three independent experiments in (A), (C),
and (D).found that the expression of VEGFR2 was lower in FOP
hiPSC-ECs compared with the control by FACS analysis,
while the expression levels of other EC genes (CD31 and
VE-cadherin) were unchanged (Figure 2C). The lower
expression of VEGFR2 may be responsible for the failure
of FOP hiPSC-ECs to propagate in vitro, and this may be
related to the activated BMP/SMAD signaling in these cells
(Figure 2B).
Moreover, we observed that ECs cultured in EGM-2 me-
dium with 2% serum showed increased expression of
EndMT markers (SLUG, N-cadherin, and TWIST; Figure 2D)
and lost the expression of endothelial-specific markers
confirmed by quantitative real-time PCR (VE-cadherin and
VEGFR2; Figure 2D) and FACS analysis (CD31, VE-cad-Stem Cellherin, and VEGFR2; Figure S2D). ECs turned to mesen-
chymal-like cells (EC-MCs) in EGM2 medium and the
expression of mesenchymal markers CD73, CD90, and
CD105 also were induced (Figures 2E, 2F, and S2E). BMP
signaling also was activated at an elevated level in FOP
EC-MCs, as demonstrated by increased ID1 expression (Fig-
ure 2G), a direct BMP/SMAD target gene (Korchynskyi and
ten Dijke, 2002). Therefore, increased BMP signaling in
FOP hiPSC-ECs correlates with impaired EC viability,
increased senescence, and increased EndMT.
Activated BMP Signaling in FOP hiPSC-Pericytes
The selected CD31 cells were cultured in DMEM with
10% fetal bovine serum (FBS) or DMEM with 10% FBSReports j Vol. 5 j 963–970 j December 8, 2015 j ª2015 The Authors 965
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Figure 2. ECs Derived from hiPSCs Un-
dergo EndMT
(A) Schematic representation shows EC and
pericyte derivation from hiPSCs.
(B) Analysis of relative expression of ID1 in
hiPSC-ECs is shown.
(C) (Left) Representative FACS analysis
for EC markers in hiPSC-ECs is shown.
Blue, unstained cells; gray, antibody as
indicated. (Right) Median fluorescence in-
tensity of EC markers expression in hiPSC-
ECs is shown.
(D) Relative gene expression analysis of EC
and EndMT markers in ECs and EC-MCs is
shown.
(E) Bright-field images of ECs and EC-MCs in
the healthy donor (C3-3) and FOP patient
(F3-8) are shown. Scale bar, 100 mm.
(F) Percentages of CD73-, CD90-, and
CD105-positive cells in EC-MCs. Represen-
tative FACS plots of CD73, CD90, and CD105
are shown in Figure S2E.
(G) Relative expression of ID1 in EC-MCs is
shown.
Data are presented as mean and SD from
three independent experiments in (B), (C),
(D), (F), and (G). The quantitative real-time
PCR results in (B), (D), and (G) were
normalized to ACTIN. See also Figure S2.supplemented with PDGF-BB and transforming growth
factor (TGF) b3 for 1 day. The homogenous population ex-
pressed pericytes and MC markers (CD73, CD90, CD105,
PDGFRb, CD146, and NG2; Figures 3A, 3B, and S3A).
SMAD1/5 phosphorylation was increased in the FOP group
in low-serum conditions, and this could be inhibited by
LDN-193189 (Figure 3C). The mRNA expression level of
ALK2 was not different in control and FOP groups (Fig-
ure S3B). The SMAD1/5 downstream target gene ID1 also
was significantly upregulated in the FOP group (Figure 3D).
Thus, FOP hiPSC-pericytes exhibited elevated SMAD1/5
levels.
FOP hiPSC-Pericyte Mineralization as an Assay to
Identify New ALK2 Inhibitors
Heterotopic bone formation in FOP follows the progressive
heterotopic endochondral ossification in soft connective
tissues, a process in which condensing mesenchymal pro-
genitor cells differentiate into chondrocytes and are even-
tually mineralized into osteoblasts and bone (Mackie
et al., 2011). We examined the effect of ALK2 R206Hmuta-
tion on chondrogenic differentiation by differentiating
hiPSC-pericytes in the two-dimensional micromass culture966 Stem Cell Reports j Vol. 5 j 963–970 j December 8, 2015 j ª2015 The Asystem without the addition of growth factors. The hiPSC-
pericytes were stained with Alcian blue for early differenti-
ation and extracellular matrix production, such as glycos-
aminoglycans (GAGs) and sulfated GAGs. After 3 days of
chondrocytic differentiation, Alcian blue staining indi-
cated that FOP hiPSC-pericytes have more GAG expression
than control hiPSC-pericytes (Figures 4A and 4B).
We further assessed the mineralization capability of FOP
hiPSC-pericytes when grown in osteogenic medium. The
osteoblast differentiation of pericytes was measured by
determining ALP activity, an early marker of osteoblast
differentiation.Histochemical staining revealed that ALP ac-
tivity in the FOP group was enhanced (Figure 4C);
F2-6 hiPSC-pericytes showed higher pSMAD1/5 signaling
compared to F3-8 (Figures 3C and 3D), which may explain
the stronger ALP activity in F2-6. Furthermore, we analyzed
osteoblast differentiation by alizarin red S staining to
detect calciumdeposition.Onday 21 and day 28 of differen-
tiation, we detected higher mineralization in the FOP group
(Figures 4D and 4E). Consistent with the ALP activity
and alizarin red S staining, quantitative real-time PCR anal-
ysis confirmed that expression of osteoblast markers ALP
and OSTEOCALCIN (OSC) (Figure 4F) was increased in theuthors
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Figure 3. Activated BMP Signaling in FOP hiPSC-Pericytes
(A) Percentages of CD73-, CD90-, CD105-, PDGFRb-, CD146-, and
NG2-positive cells in hiPSC-pericytes. Representative FACS plots
of CD73, CD90, CD105, PDGFRb, CD146, and NG2 are shown in
Figure S3A.
(B) Bright-field images of pericytes from healthy donor (UE017C1)
and FOP patient (F3-8) are shown. Scale bar, 100 mm.
(C) Western blot results showing SMAD1/5 phosphorylation in the
hiPSC-pericytes. GAPDH was used as the loading control.
(D) Relative expression of ID1. All experiments were normalized to
ACTIN.
Data are presented as mean and SD from three independent ex-
periments in (C) and (D); the average of four independent experi-
ments is shown in (A). See also Figure S3.FOP group, but we did not detect altered expression of
COLLAGEN type I alpha 1 (COL1a) in FOP and control cells
(Figure 4F). Together these data indicate that FOP hiPSC-
pericytes were prone to mineralization, which may be due
to activated BMP/SMAD signal in these cells. After pretreat-
ing pericyteswith LDN-212854, a BMP type I receptor kinase
inhibitor that is more selective for ALK2 compared withStem Cellother BMP type I receptors (Mohedas et al., 2013), we
observed that the ALP activity of FOP hiPSC-pericytes was
partly inhibited (Figure 4G).DISCUSSION
Our results demonstrated that hiPSCs could be used as
an in vitro disease model for FOP. The hiPSC-ECs and
hiPSC-pericytes can be applied to investigate themolecular
mechanisms underlying the pathology of FOP, as well as to
identify new therapeutic drugs.
We have shown that FOP hiPSCs could be established
from cells in urine using non-integrating episomal vectors.
BMP signaling contributes to the initial stage of iPSC re-
programming in mouse (Samavarchi-Tehrani et al., 2010),
but induces differentiation of hESCs (Xu et al., 2002).
Consistent with prior research (Matsumoto et al., 2013),
our FOP hiPSCs were generated without the addition of
exogenous BMP inhibitors during the reprogramming pro-
cess. We did not observe activated SMAD1/5 signaling in
FOP hiPSCs maintained in hESC medium mTeSR1 unless
these cells were placed in differentiation culture condi-
tions. This may explain why FOP hiPSCs could be main-
tained and passaged in defined medium. Besides, we
observed heterogeneous BMP/SMAD signaling and miner-
alization in FOP hiPSCs and derivative cells, indicating
that intrinsic genetic and/or epigenetic features of donor
cells may influence properties of hiPSCs and the progeny.
To eliminate the heterogeneity, the isogenic correction
FOP hiPSCs can help to facilitate more stringent screening
for effects arising from clonal variations in hiPSCs (Matsu-
moto et al., 2015).
We found that the generation and maintenance of ECs
from FOP hiPSCs were impaired. One explanation is the
elevated BMP signaling in FOP hiPSC-ECs, which resulted
in downregulation of VEGFR2 expression that mediated
VEGF-induced proliferation and survival of ECs; this may
have caused the decrease in EC viability. Inhibition of
BMP receptor kinase activity by LDN-212854 during the
vascular specification stage (from day 3 of hiPSC differenti-
ation) did not rescue the impaired FOP hiPSC-EC pheno-
types (unpublished data). BMPs are indispensable for the
formation of mesoderm where ECs originate, but they
may function as a context-dependent regulator in vascular
morphogenesis (Kim et al., 2014). In addition, a recent
publication indicated activin A signals through themutant
ALK2 R206H to stimulate HO in FOP conditional-on
knockin mice (Hatsell et al., 2015). Of note, in our EC dif-
ferentiation protocol, we used activin A and BMP4, both
of which were shown to induce SMAD1/5 signaling
through mutant ALK2 R206H (Hatsell et al., 2015). These
ligands may thus combine with the SMAD1/5 signal toReports j Vol. 5 j 963–970 j December 8, 2015 j ª2015 The Authors 967
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Figure 4. Increased Mineralization of
FOP hiPSC-Pericytes
(A) Representative Alcian blue staining of
the micromass for 3 days chondrogenic
differentiation is shown. Scale bar, 2 mm.
(B) Alcian blue staining of micromasses was
quantified by stain extraction and absor-
bance reading at 595 nm.
(C) ALP staining was performed 14 days
(D14) after maintaining in a-MEM with 10%
FBS (Ctrl) and osteogenic medium (OM).
Results are shown as representative scanned
images (left) and images taken at 43
magnification (right). Scale bar, 200 mm.
(D) The mineralization was visualized by 2%
alizarin red S staining on day 21 (D21) and
day 28 (D28). Results are shown as repre-
sentative scanned images (left) and images
taken at 43magnification (right). Scale bar,
200 mm.
(E) Alizarin red S staining on D21 and D28
was quantified by stain extraction and
absorbance reading at 570 nm.
(F) Relative gene expression analysis of ALP,
COL1a, and OSC on day 14 and day 28 of
osteoblast differentiation. All experiments
were normalized to ACTIN. Control, the
average of the results from C3-3 and
UE017C1; FOP, the average of the results from
F2-6 and F3-8.
(G) ALP assay on day 7 of F3-8 after main-
taining in OM pretreated with LDN-212854
is shown.
Data are presented as mean and SD from four
times independent experiments in (E) and
three times in (B) and (G).contribute to the FOP hiPSC-EC phenotypes that we
observed. The other explanation of low EC yields is the
increased EndoMT in ALK2-mutated ECs. Consistent with
a previous publication (Medici et al., 2010), FOP EC-MCs
showed higher expression of EndMT markers (N-cadherin
and TWIST), which might be due to the interaction of
mutant ALK2 R206H and VEGF signaling in these cells.
Further investigation of the crosstalk between BMP
signaling and VEGF signaling might contribute to the bet-
ter understanding of the EndMTmechanism in FOP lesions
and also help in identifying new drug-treatable targets to
prevent HO in FOP patients.
Lastly, we demonstrated that the mutant ALK2 R206H
contributed to the increased mineralization of FOP hiPSC-
pericytes and, as such, is a useful human in vitro disease
model for identifying and evaluating the bioactivity of
ALK2 inhibitors. More evidence indicates that MCs are the
major contributors of HO (Wosczyna et al., 2012), while
ECs indirectly contribute to osteogenic differentiation by968 Stem Cell Reports j Vol. 5 j 963–970 j December 8, 2015 j ª2015 The Aacting in a paracrine manner via crosstalk between ECs
andMCs (Bidarra et al., 2011; Lin et al., 2014). Even though
Matsumoto et al. partly exhibited FOP phenotypes by
directly differentiating hiPSCs into osteoblast cells
(Matsumoto et al., 2013), they provided little evidence of
how the specific cell types contributed to the increased
mineralization. To further clarify the mineralization capac-
ity of FOP hiPSCs in vitro, we differentiated hiPSCs into
pericytes. ALP activity of FOP hiPSC-pericytes can be in-
hibited by pretreating with BMP inhibitor LDN-212854.
As the ALP assay has been used as a high-throughput
screening (HTS) readout for screening regulators in osteo-
genic differentiation (Alves et al., 2011), our platform could
be used for drug screening and further verifying the bioac-
tivity of ALK2 inhibitors in the future.
Even though in this study we only studied ECs and peri-
cytes, the twomostwell-knownHOprogenitor cells in FOP,
it is possible other unidentified cells types also may be
involved in the HO process in FOP. Due to the pluripotentuthors
characterization of hiPSCs, FOP hiPSCs can be differenti-
ated into other (unknown) progenitor cells to discover
the underlyingmolecular mechanisms of HO in the future.EXPERIMENTAL PROCEDURES
Primary human cells were obtained with informed consent. Exper-
iments involving human subjects were approved by Institutional
Review Board (IRB) GIBH-IRB02-2009002 at Guangzhou Institutes
of Biomedicine and Health (GIBH) and 12/467 (2013 January) at
VU University Medical Center. The animal research was approved
by the IRB at GIBH (2010012). The generation and differentiation
of hiPSCs were described previously (Orlova et al., 2014; Xue et al.,
2013). Differences between the control group and the FOP group
were evaluated by t test or one-way ANOVA with Tukey’s multiple
comparison tests (ns, not significant; *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001). For further information, see the Supple-
mental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and three figures and can be found with this article on-
line at http://dx.doi.org/10.1016/j.stemcr.2015.10.020.
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